Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathway

Fig. 1

Up-regulation of Nrf2 in human PDAC and predicts poor prognosis. a The paired tumor and adjacent normal tissues in pancreatic cancer patients were stained with IHC (Scale bar: 50 & 200 μm) for detection of Nrf2 protein levels (n = 4). b The expression level of NFE2L2 (Nrf2) in PDAC (n = 179) and normal pancreas (n = 171) was analyzed using GEPIA. c Nrf2 expression in Miapaca-2, Capan-2, PANC-1, GSE-1 and Hs27 cells were detected by western blot. d Expression of Nrf2 in different clinical stages of PDAC patients. e–f Kaplan–Meier curve showed the correlation between Nrf2 expression and disease-free survival, overall survival of PDAC patients analyzed using GEPIA. j-h Immunoblotting for Nrf2 expression in GEM-treated Miapaca-2, Capan-2 and PANC-1 cells. β-actin was used as a loading control. i The mRNA expression of Nrf2 in Miapaca-2, Capan-2, and PANC-1 cells. The cells were treated with GEM for 48 h. Data were presented as the mean ± SD. *p < 0.05, **p < 0.01 and ***p < 0.001

Back to article page